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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMangioplasty: dizziness (110), bilateral weakness (12), visual changes 14), diplopia
(12), drop attacks (24), TIA (15), ataxia (6). A protection device (ﬁlter) used in 12 pts.
25 SA angioplasties performed at the same time of VAS, 10 CA. All angioplasties
performed by femoral approach, 4 by brachial approaches after failure of femoral
approach. (2 successes).
Results: Technical success 118/120 (99%). 6 lesions treated by angioplasty alone: 3
VO (ﬁrst 3 pts. 2 V1, 1 V2 lesion). 1 pt (inﬂammatory disease) treated by cutting
balloon alone. 111 lesions treated with stents (direct stenting: 96). Peripheral balloon
expandable stents (n¼23), self expandable stents (n¼4 for 3 V1 and one V2 lesions).
88 coronary stents (20 DES). 1 pt developed a TIA during the procedure. No
neurological complications at 30 days Clinical success 112/114 (99%) Post-procedure
arterial diameter: 4,60  0,8 mm (4-6). Mean residual stenosis 2,5  3,9 %. In 12 pts
treated with protection devices, visible debris removed in 9 (6 Filterwire, 2 Fibernet) 1
Angioguard with the same amount of debris as during Carotid Stenting) 9 pts (8%)
developed a symptomatic restenosis during the follow-up (mean: 33.4.29.9 months),
3 after PTA alone, 5 after PTA and stent (1 occlusion treated medically, 7 stenoses
successfully treated with PTA). No restenosis after DES implantation at 1 year.
Conclusions: VAS can be performed safely and effectively with a high technical
success rate, a low complication rate, a low restenosis rate and a durable clinical
success in patients with symptomatic VA stenosis. Stents seem to improve immediate
and long-term results. The role of protection devices and D.E.S has to be discussed.Carotid Intervention
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Proximal occlusion versus distal ﬁlter for cerebral protection during carotid
stenting: a meta-analysis of MRI studies
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Background: Proximal occlusion (PO) and distal ﬁlter (DF) serve for cerebral
embolic protection during carotid artery stenting (CAS). The incidence of new cere-
bral lesions at diffusion-weighted magnetic resonance imaging (DW-MRI) represents
a surrogate endpoint for embolization, though the clinical impact is controversial. We
perform a meta-analysis of DW-MRI studies comparing PO and DF during CAS.
Methods: Scientiﬁc databases and websites were searched. The primary endpoint was
the incidence of new cerebral lesions at DW-MRI; secondary endpoints were the
incidence of new ipsilateral and new contralateral cerebral lesions at DW-MRI and
death/cerebrovascular events (CVE).
Results: A total of 292 patients from 6 studies received CAS with PO (n¼ 143) or DF
(n¼ 149). At DW-MRI after 48 hours 129 patients (49%) presented new cerebral
lesions. PO versus DF did not reduce the risk of new cerebral lesions (OR [95%
conﬁdence interval] 0.74 [0.26-2.07], P¼ 0.57), neither ipsilateral (0.72 [0.24-2.16],
P¼ 0.55), nor contralateral (0.55 [0.26-1.20], P¼ 0.13). At 90-day follow-up, PO
versus DF did not reduce the risk of death/CVE (0.58 [0.18-1.90], P¼ 0.37). High-
grade baseline stenoses and the presence of symptoms signiﬁcantly modiﬁed the risk
estimates for new cerebral lesions. However, there was no relationship between new
cerebral lesions and the risk of death/CVE.
Conclusions: In this meta-analysis, one half of patients receiving protected CAS
developed new embolic cerebral lesions at DW-MRI, although the overwhelming
majority was asymptomatic. Cerebral protection with PO versus DF did neither reduce
cerebral embolization nor impact clinical outcomes. The grade of baseline stenosis and
the presence of symptoms impact the risk of cerebral embolization associated with
protected CAS.
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Could Staged Carotid Stenting with CABG be non-inferior to combined Carotid
Endarterectomy and CABG for Carotid and Coronary Revascularization?
A Meta-Analysis of Prospective Studies
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Background: Carotid stenting (CS) is considered to be non-inferior to carotid end-
arterectomy (CEA) for treatment of symptomatic carotid disease with similar stoke
and death rates. It is still to be determined if staged CS followed by CABG could beJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Caalso non-inferior to combined CEA and CABG for the concomitant presence of
coronary and carotid artery disease. Therefore we aimed to evaluate the non-inferiority
of staged CS compared to combined CEA and CABG by using all the prospective
available studies.
Methods: Pub Med, Chocrane and Scopus were systematically searched up to April
2014. Subjects of analysis were 30 days post surgery incidence of stroke and death for
carotid and coronary revascularization using either CS or CEA with CABG. We used
Fixed or Random Effect analysis using the Cochrane Handbook of Systematic
Reviews.
Results: Out of 350 articles, three prospective studies were identiﬁed and disclosed a
total of 94 patients on the CS and 140 in the CEA group respectively. There was a
trend towards lower stroke in the CAS group compared to the CEA (4.2% vs 9.2%,
p¼0.1; Figure 1.A) and no difference on mortality rate (5.3% vs. 7.8%, p¼0.42;
Figure 1.B).
Conclusions: Our analysis suggests that staged CS and CABG might not be inferior to
combined CEA and CABG. Also the overall mean incidence of 30 days stroke is
below the average reported on most observational studies. Therefore clinical ran-
domized studies are warranted.TCT-550
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Background: Circulating biomarkers of atherosclerosis, in isolation, are largely
ineffective in risk stratiﬁcation of carotid plaque (CS) symptomatic transformation
while plaque morphology is increasingly implicated. Intravascular ultrasound (IVUS,
20MHz transducer) provides axial resolution 0.12mm. However, conventional
-phenotypic- virtual histology (VH-IVUS) plaque evaluation has poor between-cen-
ter/-observer reproducibility. To provide basis for prospective comprehensive evalu-
ation, we sought to determine whether quantitative measures of key rupture-risk
plaque components are related to selected circulating biomarkers.
Methods:We developed an algorithm for fully-quantitative VH-IVUS analysis of key
plaque components known for their role in plaque rupture/thrombosis. Inter-transducer
and inter-observer reproducibility of qVH-IVUS analysis including minimal ﬁbrous
cap (FC) thickness, and peak conﬂuent NC area, thickness and arc. Next we employed
the qVH-IVUS algorithm to evaluate CS lesions in 200 consecutive patients (age 47–
83, 63.4% men, h/o CS-attributable symptoms in 50.3%) presenting for potential CS
revascularization and determined the levels of a panel of biomarkers.
Results: qVH-IVUS revealed signiﬁcant differences in minimal FC thickness
(0.410.04 v 0.340.05 v 0.160.02 v 0.190.03mm), peak conﬂ NC area (3.00.2
v 2.50.3 v 4.40.4 v 3.40.5mm2), arc (87.16 v 67.26 v 121.69 v
94.09deg) and thickness (0.880.04 v 1.070.07 v 1.340.06 v 1.160.11mm);
asympt CS in absence of contralat symptoms, asympt CS+contralat symptoms,
recently symptomatic and remotely symptomatic CS, p< 0.001 all. hsCRP was not
correlated with min FC (p¼0.74) or NC area (p¼0.48). TIMP correlated with min FC
(r¼0.34, p¼0.001). Modest though highly signiﬁcant correlations were identiﬁed
between Lp-PLA2 and conﬂ NC area (r¼0.3, p¼0.0001), HDL and conﬂ NC thckn
(r¼-0.21, p¼0.002). Selected ﬁbrin clot properties showed an association with VH-
determined plaque content. Fibrinogen level correlated with % plaque ﬁbrotic content
(r¼0.19, p¼0.008).
Conclusions: These ﬁndings provide novel insights into circulating biomarker/
quantitative plaque morphology associations that may be relevant to risk
stratiﬁcation.rotid Intervention B161
